Division of Allergy and Infectious Diseases, University of Washington, Seattle.
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
JAMA Netw Open. 2022 Jan 4;5(1):e2142796. doi: 10.1001/jamanetworkopen.2021.42796.
The SARS-CoV-2 viral trajectory has not been well characterized in incident infections. These data are needed to inform natural history, prevention practices, and therapeutic development.
To characterize early SARS-CoV-2 viral RNA load (hereafter referred to as viral load) in individuals with incident infections in association with COVID-19 symptom onset and severity.
DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study was a secondary data analysis of a remotely conducted study that enrolled 829 asymptomatic community-based participants recently exposed (<96 hours) to persons with SARS-CoV-2 from 41 US states from March 31 to August 21, 2020. Two cohorts were studied: (1) participants who were SARS-CoV-2 negative at baseline and tested positive during study follow-up, and (2) participants who had 2 or more positive swabs during follow-up, regardless of the initial (baseline) swab result. Participants collected daily midturbinate swab samples for SARS-CoV-2 RNA detection and maintained symptom diaries for 14 days.
Laboratory-confirmed SARS-CoV-2 infection.
The observed SARS-CoV-2 viral load among incident infections was summarized, and piecewise linear mixed-effects models were used to estimate the characteristics of viral trajectories in association with COVID-19 symptom onset and severity.
A total of 97 participants (55 women [57%]; median age, 37 years [IQR, 27-52 years]) developed incident infections during follow-up. Forty-two participants (43%) had viral shedding for 1 day (median peak viral load cycle threshold [Ct] value, 38.5 [95% CI, 38.3-39.0]), 18 (19%) for 2 to 6 days (median Ct value, 36.7 [95% CI, 30.2-38.1]), and 31 (32%) for 7 days or more (median Ct value, 18.3 [95% CI, 17.4-22.0]). The cycle threshold value has an inverse association with viral load. Six participants (6%) had 1 to 6 days of viral shedding with censored duration. The peak mean (SD) viral load was observed on day 3 of shedding (Ct value, 33.8 [95% CI, 31.9-35.6]). Based on the statistical models fitted to 129 participants (60 men [47%]; median age, 38 years [IQR, 25-54 years]) with 2 or more SARS-CoV-2-positive swab samples, persons reporting moderate or severe symptoms tended to have a higher peak mean viral load than those who were asymptomatic (Ct value, 23.3 [95% CI, 22.6-24.0] vs 30.7 [95% CI, 29.8-31.4]). Mild symptoms generally started within 1 day of peak viral load, and moderate or severe symptoms 2 days after peak viral load. All 535 sequenced samples detected the G614 variant (Wuhan strain).
This cohort study suggests that having incident SARS-CoV-2 G614 infection was associated with a rapid viral load peak followed by slower decay. COVID-19 symptom onset generally coincided with peak viral load, which correlated positively with symptom severity. This longitudinal evaluation of the SARS-CoV-2 G614 with frequent molecular testing serves as a reference for comparing emergent viral lineages to inform clinical trial designs and public health strategies to contain the spread of the virus.
尚未很好地描述 SARS-CoV-2 病毒轨迹在新发病例感染中。这些数据对于了解自然史、预防措施和治疗开发非常重要。
描述新发病例感染中个体的早期 SARS-CoV-2 病毒 RNA 载量(以下简称病毒载量)与 COVID-19 症状发作和严重程度的关系。
设计、地点和参与者:这是一项前瞻性队列研究,对 2020 年 3 月 31 日至 8 月 21 日期间来自美国 41 个州的最近接触过 SARS-CoV-2 患者(<96 小时)的 829 名无症状社区参与者进行的远程研究进行了二次数据分析。研究了两个队列:(1)基线时 SARS-CoV-2 阴性但在研究随访期间检测为阳性的参与者,以及(2)在随访期间有 2 次或更多次阳性拭子的参与者,无论初始(基线)拭子结果如何。参与者每天采集中鼻甲拭子样本用于 SARS-CoV-2 RNA 检测,并在 14 天内保持症状日记。
实验室确诊的 SARS-CoV-2 感染。
总结了新发病例感染中的观察到的 SARS-CoV-2 病毒载量,并使用分段线性混合效应模型估计了与 COVID-19 症状发作和严重程度相关的病毒轨迹特征。
在随访期间,共有 97 名参与者(55 名女性[57%];中位年龄为 37 岁[IQR,27-52 岁])发生新发病例感染。42 名参与者(43%)的病毒脱落持续 1 天(中位峰值病毒载量循环阈值[Ct]值为 38.5[95%CI,38.3-39.0]),18 名参与者(19%)持续 2-6 天(中位 Ct 值为 36.7[95%CI,30.2-38.1]),31 名参与者(32%)持续 7 天或更长时间(中位 Ct 值为 18.3[95%CI,17.4-22.0])。Ct 值与病毒载量呈反比关系。6 名参与者(6%)有 1-6 天的病毒脱落,持续时间被截断。脱落期的峰值平均(SD)病毒载量为第 3 天(Ct 值为 33.8[95%CI,31.9-35.6])。根据拟合 129 名参与者(60 名男性[47%];中位年龄为 38 岁[IQR,25-54 岁])的 2 次或更多次 SARS-CoV-2 阳性拭子样本的统计模型,报告中度或重度症状的人比无症状者的峰值平均病毒载量更高(Ct 值分别为 23.3[95%CI,22.6-24.0]和 30.7[95%CI,29.8-31.4])。轻度症状通常在峰值病毒载量后 1 天内开始,中度或重度症状在峰值病毒载量后 2 天开始。所有 535 个测序样本均检测到 G614 变异体(武汉株)。
本队列研究表明,发生 SARS-CoV-2 G614 新发病例感染与快速的病毒载量峰值随后缓慢衰减有关。COVID-19 症状发作通常与病毒载量峰值同时发生,与症状严重程度呈正相关。这项对 SARS-CoV-2 G614 的纵向评估以及频繁的分子检测为比较新兴病毒谱系提供了参考,以告知临床试验设计和公共卫生策略,以遏制病毒的传播。